Reuters: Investors await bone drug data from Amgen

[NaDiNe]

Investors await bone drug data from Amgen
      

BOSTON (Reuters) - Results due next week from a trial of Amgen Inc's experimental osteoporosis drug denosumab will represent a pivotal moment for the world's biggest biotechnology company as it struggles with declining sales of its flagship anemia drugs.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login